ESTIMATING THE COST EFFECTIVENESS IN THE UK OF VILDAGLIPTIN COMPARED TO PIOGLITAZONE AS ADD-ON THERAPY TO METFORMIN USING THE SHEFFIELD TYPE 2 DIABETES MODEL

被引：1
|
作者：
Brennan, A. [1 ]
Gillett, M. [1 ]
Duenas, A. [1 ]
机构：
[1] Univ Sheffield, Sheffield, S Yorkshire, England
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66666-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
下载
收藏
页码：A501 / A501
页数：1
相关论文
共 50 条
  • [21] Mechanism Based Pharmacokinetic Pharmacodynamic Modeling of Vildagliptin as an Add-on to Metformin for Subjects with Type 2 Diabetes
    Eftekhari, Marziyeh
    Vahidi, Omid
    CMES-COMPUTER MODELING IN ENGINEERING & SCIENCES, 2018, 114 (02): : 153 - 171
  • [22] Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes
    Charbonnel, B
    Schernthaner, G
    Brunetti, P
    Matthews, DR
    Urquhart, R
    Tan, MH
    Hanefeld, M
    DIABETOLOGIA, 2005, 48 (06) : 1093 - 1104
  • [23] Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes
    B. Charbonnel
    G. Schernthaner
    P. Brunetti
    D. R. Matthews
    R. Urquhart
    M. H. Tan
    M. Hanefeld
    Diabetologia, 2005, 48 : 1093 - 1104
  • [24] Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany
    Goke, R.
    Gruenberger, J. B.
    Bader, G.
    Dworak, M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (05) : 785 - 789
  • [25] Add-on therapies to metformin for type 2 diabetes
    Shomali, Mansur
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (01) : 47 - 62
  • [26] Better adherence with vildagliptin add-on to metformin than sulphonylurea add-on to metformin among Muslim patients with type 2 diabetes mellitus fasting during Ramadan
    Hanif, W.
    Malik, W.
    Hassanein, M.
    Kamal, A.
    Geransar, P.
    Lister, N.
    Andrews, C.
    Barnett, A. H.
    DIABETOLOGIA, 2011, 54 : S342 - S342
  • [27] COST-EFFECTIVENESS OF ADD-ON THERAPIES TO METFORMIN: THE IMPACT OF MEDICATION ADHERENCE FOR TYPE 2 DIABETES MELLITUS
    Ho, C. M.
    Yeh, T. H.
    Lai, Y. T.
    VALUE IN HEALTH, 2021, 24 : S80 - S80
  • [28] The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Postema, R.
    Townsend, R.
    Roudaut, M.
    DIABETIC MEDICINE, 2015, 32 (07) : 890 - 898
  • [29] CHOICE OF THE ADD-ON THERAPY TO METFORMIN IN TYPE 2 DIABETES PATIENTS IN ROMANIA
    Brozi, J.
    Brunerova, L.
    ACTA ENDOCRINOLOGICA-BUCHAREST, 2017, 13 (03) : 375 - 375
  • [30] Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting
    Melzer Cohen, Cheli
    Davis, Carla
    Shalev, Varda
    Chodick, Gabriel
    JOURNAL OF DIABETES, 2018, 10 (01) : 68 - 72
12345